{
    "nctId": "NCT01281150",
    "briefTitle": "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors",
    "officialTitle": "A Phase 1 Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors",
    "overallStatus": "COMPLETED",
    "conditions": "Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Triple-Negative Breast Carcinoma",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "MTD defined as the dose level one level below the lowest dose where greater than or equal to 2 patients experience a DLT assessed by National Cancer Institute (NCI) CTCAE v. 4.0",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically or cytologically confirmed solid tumor that has evidence of metastatic spread (stage IV) or is locally advanced and unresectable\n\n  * Patients with breast cancer may have estrogen receptor positive or negative (ER+ or ER-) disease\n  * Patients with breast cancer may not be human epidermal growth receptor -2 (HER2)-positive ( 3+), or fluorescent in situ hybridization (FISH) ratio \\> 2.2\n  * Patients in the biopsy expansion cohort must have \"triple negative\" breast cancer defined as:\n\n    * Estrogen receptor staining \\< 10%; progesterone receptor staining \\<10%; Her 2 \\< 2.2 by FISH, or immunohistochemistry (IHC) 0-2+\n* Patients may have been previously treated\n\n  * In the dose escalation cohort, there is no limit to prior therapies\n  * In the expansion cohort, patients may have only had 1-3 prior regimens for metastatic disease\n  * Patients may have received prior carboplatin, paclitaxel, or poly (ADP-ribose) polymerase (PARP) inhibitor therapy as part of their previous treatment regimens\n\n    * However, patients may NOT have received prior therapy with paclitaxel, carboplatin, and PARP inhibitor in combination\n  * Patients must not have received chemotherapy within 4 weeks of starting study (or 6 weeks if prior treatment was with carmustine \\[BCNU\\] or mitomycin C)\n  * Patients must not have received radiation within 2 weeks of starting study\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS)\\< 2 (Karnofsky \\> 60%)\n* Life expectancy \\> 2 months\n* Absolute neutrophil count (ANC) \\>= 1,500/mcL\n* Platelet count \\>= 100,000/mcL\n* Total bilirubin =\\< 1.5 times upper limit of normal (ULN)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\]/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \\[SGPT\\]) =\\< 2.5 times ULN\n* Creatinine normal within normal institutional limits OR creatinine clearance \\>= 60 mL/min/1.73m\\^2 for patients with creatinine levels above institutional normal\n* Must able to swallow pills\n* Pregnant women are excluded from this study\n\n  * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately\n* Ability to understand and the willingness to sign a written informed consent document\n* Patients enrolled in the expanded cohort with mandatory biopsies must:\n\n  * Have accessible tumors\n  * Not be on therapeutic anticoagulation\n  * Have signed informed consent form\n\nExclusion Criteria:\n\n* Patients who have had chemotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or radiotherapy within 2 weeks (4 weeks for central nervous system \\[CNS\\] metastases) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier\n* Patients may not be receiving any other investigational agents\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study\n* Concurrent treatment with bisphosphonates, or other bone anti-resorptive agent such as denosumab is allowed; concurrent treatment with hormonal therapy (tamoxifen, ovarian suppression with gonadotropin-releasing hormone \\[GNRH\\] agonists, aromatase inhibitors) or trastuzumab therapy is NOT allowed in breast cancer patients; prostate cancer patients may continue GNRH agents\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with veliparib\n* Active seizure or history of seizure disorder\n* Patients with CNS metastases must be stable after therapy for CNS metastases (such as surgery, radiotherapy or stereotactic radiosurgery) for \\> 3 months and must be off steroid treatment prior to study enrollment\n* Patients who undergo biopsy as part of the study in the expanded dose cohort should not be on anti-coagulants or have a pre-existing coagulopathy\n* Peripheral neuropathy of severity greater than grade 1",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}